Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | KDM1A | O60341 | 1/20 | 0.47 |
| ▸ | DAO | P14920 | 1/20 | 0.46 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL663 | 0.85 | POLB (0.47) | KMT2AKDM1ADAOPOLB | |
| SCHEMBL1882418 | 0.82 | KMT2A (0.50) | KMT2AKDM1ADAOMCL1POLB | |
| SCHEMBL1744581 | 0.80 | KMT2A (0.53) | KMT2AKDM1ADAOMCL1POLB | |
| SCHEMBL3806253 | 0.80 | KMT2A (0.48) | KMT2AKDM1ADAOMCL1POLB | |
| SCHEMBL14380468 | 0.80 | KMT2A (0.48) | KMT2AKDM1ADAOMCL1POLB | |
| SCHEMBL9243039 | 0.80 | KMT2A (0.48) | KMT2AKDM1ADAOMCL1POLB | |
| SCHEMBL7138325 | 0.80 | KDM1A (0.50) | KMT2AKDM1ADAOMCL1POLB | |
| SCHEMBL7072559 | 0.78 | KMT2A (0.47) | KMT2AKDM1ADAOMCL1POLB | |
| SCHEMBL11389628 | 0.77 | HTT (0.43) | KMT2A | |
| SCHEMBL22292651 | 0.77 | OPRM1 (0.37) | KMT2APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101166730-A | Cinnoline compounds and their use as liver X receptor modilators | WYETH CORP (US) | 2008-04-23 | — | — | CN | claimed |
| US-20240400499-A1 | NOVEL AMINO ACID DERIVATIVES | PEPTIDREAM INC (JP) | 2024-12-05 | — | — | US | disclosed |
| WO-2022109078-A1 | AROMATIC BORON-CONTAINING COMPOUNDS AND INSULIN ANALOGS | PROTOMER TECHNOLOGIES INC. (US) | 2022-05-27 | — | — | WO | disclosed |
| US-20180186755-A1 | LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF | PHARMAKEA INC (US) | 2018-07-05 | — | — | US | disclosed |
| EP-3317258-A1 | LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF | Pharmakea, Inc. (US) | 2018-05-09 | — | — | EP | disclosed |
| WO-2018048930-A1 | LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF | PHARMAKEA, INC. (US) | 2018-03-15 | — | — | WO | disclosed |
| WO-2017003862-A1 | LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF | PHARMAKEA, INC. (US) | 2017-01-05 | — | — | WO | disclosed |
| US-9346795-B2 | Substituted sulfonamides useful as antiapoptotic Bcl inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-05-24 | — | — | US | disclosed |
| US-9242970-B2 | Lactam derivatives useful as orexin receptor antagonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2016-01-26 | — | — | US | disclosed |
| EP-2638008-B1 | LACTAM DERIVATIVES USEFUL AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2015-07-01 | — | — | EP | disclosed |
| US-20030225071-A1 | HIV protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis | PFIZER INC. | 2003-12-04 | — | — | US | disclosed |
| EP-1225894-A4 | FAB I INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2003-01-08 | — | — | EP | disclosed |
| WO-2002100844-A2 | HIV PROTEASE INHIBITORS, COMPOSITIONS CONTAINING THE SAME, THEIR PHARMACEUTICAL USES AND MATERIALS FOR THEIR SYNTHESIS | AGOURON PHARMACEUTICALS, INC. (US) | 2002-12-19 | — | — | WO | disclosed |
| EP-0767792-A4 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 2002-11-20 | — | — | EP | disclosed |
| EP-1225894-A1 | FAB I INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2002-07-31 | — | — | EP | disclosed |
| WO-2001026652-A1 | FAB I INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-04-19 | — | — | WO | disclosed |
| US-5977101-A | Benzimidazoles/Imidazoles Linked to a Fibrinogen Receptor Antagonist Template Having Vitronectin Receptor Antagonist Activity | SMITHKLINE BEECHAM CORPORATION (US) | 1999-11-02 | — | — | US | disclosed |
| CN-1156995-A | Vitronectin receptor antagonists | SMITHKLINE BEECHAM CORP (US) | 1997-08-13 | — | — | CN | disclosed |
| EP-0767792-A1 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1997-04-16 | — | — | EP | disclosed |
| WO-1996000730-A1 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1996-01-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180186755-A1 | LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF | LOXL2, LOXL1, LOX | KMT2A 1243/4885KDM1A 742/4885DAO 60/4885 |
| US-20030225071-A1 | HIV protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis | SERPINB1, FURIN, PEPD | KMT2A 3492/4885KDM1A 1682/4885DAO 553/4885 |
| US-20240400499-A1 | NOVEL AMINO ACID DERIVATIVES | BCAT1, BCAT2, PELP1 | KMT2A 3415/4885KDM1A 4620/4885DAO 39/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.